sibutramine

sibutramine /si·bu·tra·mine/ (si-bu´trah-mēn″) an anorectic used as the hydrochloride salt in the management of obesity.

---

si·bu·tra·mine (s-bytr-mn, -mn)

n.

A drug that suppresses appetite by inhibiting the reuptake of norepinephrine and serotonin, used in the management of obesity.

---

Sibutramine

An appetite-suppressing drug that may increase the activity of norepinephrine and serotonin in the brain.

Mentioned in: Weight Loss Drugs

---

sibutramine,

an appetite suppressant.

indications It is used to treat obesity in conjunction with other treatments.

contraindications The following factors prohibit its use: known hypersensitivity to this drug, hypothyroidism, anorexia nervosa, severe hepatic/renal disease, uncontrolled hypertension, cerebrovascular accident, history of coronary artery disease, congestive heart failure, arrhythmias, pregnancy, and lactation.

adverse effects Tachycardia is a life-threatening effect of this drug. Other adverse effects include headache, insomnia, seizures, stimulation, drowsiness, dizziness, nervousness, emotional lability, hypotension, palpitations, vasodilation, anorexia, constipation, dry mouth, taste aberration, nausea, increased appetite, dysmenorrhea, laryngitis, pharyngitis, rhinitis, sinusitis, rash, and sweating.

---

sibutramine [si-bu´trah-mēn″]

an appetite suppressant used as the hydrochloride salt in treatment of obesity; administered orally.

---

sibutramine (sībū´trmēn),

n an FDA-approved prescription drug for weight loss containing a combination of serotonin and andronergics that has been shown to promote a feeling of fullness while apparently not influencing hunger; Meridia is an example.

---

sibutramine

Meridia^® Obesity A central, appetite-suppressing agent that blocks reuptake of serotonin and norepinephrine, and, to a lesser extent dopamine; it provides a sensation of fullness from less food, and ↑ metabolism Indications Obese Pts with an initial BMI of ≥ 30 kg/m2 or ≥ 27 kg/m2 with other factors–eg, HTN, DM, dyslipidemia Cons Sibutramine is a Schedule IV Controlled Substance Adverse effects Headache, dry mouth, anorexia, constipation Contraindications Concurrent MAOIs, other central appetite suppressants, anorexia nervosa. See Obesity.